Active, not recruitingPhase 3NCT02665065
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Studying Acute promyelocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Actinium Pharmaceuticals
- Principal Investigator
- Avinash Desai, MDActinium Pharmaceuticals
- Intervention
- Iomab-B(drug)
- Enrollment
- 153 target
- Eligibility
- 55 years · All sexes
- Timeline
- 2016 – 2026
Study locations (24)
- Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
- Yale Cancer Center, New Haven, Connecticut, United States
- Georgetown University Medical Center, Washington D.C., District of Columbia, United States
- Mayo Clinic, Jacksonville, Florida, United States
- Loyola University Medical Center, Maywood, Illinois, United States
- University of Iowa, Iowa City, Iowa, United States
- The University of Kansas Cancer Center, Westwood, Kansas, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- University of Nebraska Medical Center, Omaha, Nebraska, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- Weill Cornell Medicine, New York, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Stony Brook University, Stony Brook, New York, United States
- University of North Carolina Hospital, Chapel Hill, North Carolina, United States
- +9 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02665065 on ClinicalTrials.govOther trials for Acute promyelocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07563179Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaShenzhen University General Hospital
- RECRUITINGPHASE3NCT07504458Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic LeukemiaQuetzal Therapeutics
- RECRUITINGPHASE3NCT07223814Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)Stichting Hemato-Oncologie voor Volwassenen Nederland
- ACTIVE NOT RECRUITINGNANCT07187505Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic LeukemiaAnhui Medical University
- RECRUITINGPHASE3NCT07503730Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).First Affiliated Hospital Xi'an Jiaotong University
- ENROLLING BY INVITATIONNANCT06697327Daunorubicin + Cytarabine + Venetoclax in de Novo AMLAnhui Medical University
- RECRUITINGPHASE1NCT06313437Revumenib in Combination With 7+3 + Midostaurin in AMLRichard Stone, MD
- RECRUITINGPHASE3NCT06578247Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AMLDaiichi Sankyo